Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$3.43 USD
+0.07 (2.08%)
Updated Aug 15, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Pyxis Oncology, Inc. (PYXS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.00 | $12.00 | $7.00 | 162.39% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Pyxis Oncology, Inc. comes to $9.00. The forecasts range from a low of $7.00 to a high of $12.00. The average price target represents an increase of 162.39% from the last closing price of $3.43.
Analyst Price Targets (6 )
Broker Rating
Pyxis Oncology, Inc. currently has an average brokerage recommendation (ABR) of 1.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on seven recommendations.
Of the eight recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 87.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 85.71%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 6 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.13 | 1.13 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | William Blair | Andy T Hsieh | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/26/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/15/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/2/2024 | SVB Securities | Jeffrey La Rosa | Strong Buy | Strong Buy |
3/22/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
2/9/2024 | BTIG | Kaveri Pohlman | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.13 |
ABR (Last week) | 1.13 |
# of Recs in ABR | 8 |
Average Target Price | $9.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 94 of 253 |
Current Quarter EPS Est: | -0.29 |